These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 38705935

  • 21. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
    Chiu WY, Shih SR, Tseng CH.
    Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
    [Abstract] [Full Text] [Related]

  • 22. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.
    Derosa G, Maffioli P.
    Curr Clin Pharmacol; 2012 Aug; 7(3):214-28. PubMed ID: 22432846
    [Abstract] [Full Text] [Related]

  • 23. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
    Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, Greig NH.
    J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
    [Abstract] [Full Text] [Related]

  • 24. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells.
    Peyot ML, Gray JP, Lamontagne J, Smith PJ, Holz GG, Madiraju SR, Prentki M, Heart E.
    PLoS One; 2009 Jul 13; 4(7):e6221. PubMed ID: 19593440
    [Abstract] [Full Text] [Related]

  • 25. Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway.
    Chang G, Liu J, Qin S, Jiang Y, Zhang P, Yu H, Lu K, Zhang N, Cao L, Wang Y, Li Y, Zhang D.
    Int J Mol Med; 2018 Mar 13; 41(3):1693-1703. PubMed ID: 29286061
    [Abstract] [Full Text] [Related]

  • 26. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, Poulsen SS.
    Regul Pept; 2012 Nov 10; 179(1-3):91-100. PubMed ID: 22989472
    [Abstract] [Full Text] [Related]

  • 27. The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity.
    Burmeister MA, Brown JD, Ayala JE, Stoffers DA, Sandoval DA, Seeley RJ, Ayala JE.
    Am J Physiol Endocrinol Metab; 2017 Dec 01; 313(6):E651-E662. PubMed ID: 28811293
    [Abstract] [Full Text] [Related]

  • 28. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
    Wu X, Li S, Xue P, Li Y.
    Exp Cell Res; 2017 Nov 15; 360(2):281-291. PubMed ID: 28919123
    [Abstract] [Full Text] [Related]

  • 29. Glucagon-like peptide-1 receptor agonist exendin 4 ameliorates diabetes-associated vascular calcification by regulating mitophagy through the AMPK signaling pathway.
    Chen K, Jin HJ, Wu ZH, Zhang BF, Wu J, Huang ZY, Huang YP, Lu XW, Zheng XT.
    Mol Med; 2024 May 08; 30(1):58. PubMed ID: 38720283
    [Abstract] [Full Text] [Related]

  • 30. Exendin-4 reverses high glucose-induced endothelial progenitor cell dysfunction via SDF-1β/CXCR7-AMPK/p38-MAPK/IL-6 axis.
    Yang Y, Zhou Y, Wang Y, Wei X, Wu L, Wang T, Ma A.
    Acta Diabetol; 2020 Nov 08; 57(11):1315-1326. PubMed ID: 32556532
    [Abstract] [Full Text] [Related]

  • 31. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S, de Kort M, Irwin N, Moffett RC, Dokter WH, Bos ES, Miltenburg AM, Flatt PR.
    Diabetes Obes Metab; 2015 Aug 08; 17(8):760-70. PubMed ID: 25929155
    [Abstract] [Full Text] [Related]

  • 32. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
    Mul JD, Begg DP, Barrera JG, Li B, Matter EK, D'Alessio DA, Woods SC, Seeley RJ, Sandoval DA.
    Am J Physiol Regul Integr Comp Physiol; 2013 Jul 01; 305(1):R68-77. PubMed ID: 23616105
    [Abstract] [Full Text] [Related]

  • 33. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
    Li Y, Tweedie D, Mattson MP, Holloway HW, Greig NH.
    J Neurochem; 2010 Jun 01; 113(6):1621-31. PubMed ID: 20374430
    [Abstract] [Full Text] [Related]

  • 34. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS, Jun HS.
    Metabolism; 2014 Jan 01; 63(1):9-19. PubMed ID: 24140094
    [Abstract] [Full Text] [Related]

  • 35. The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways.
    Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P, Ghigo E, Camussi G, Zanone MM.
    Diabetologia; 2012 Apr 01; 55(4):1058-70. PubMed ID: 22231124
    [Abstract] [Full Text] [Related]

  • 36. PAS kinase is a nutrient and energy sensor in hypothalamic areas required for the normal function of AMPK and mTOR/S6K1.
    Hurtado-Carneiro V, Roncero I, Egger SS, Wenger RH, Blazquez E, Sanz C, Alvarez E.
    Mol Neurobiol; 2014 Oct 01; 50(2):314-26. PubMed ID: 24445950
    [Abstract] [Full Text] [Related]

  • 37. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.
    Liu Z, Habener JF.
    J Biol Chem; 2008 Mar 28; 283(13):8723-35. PubMed ID: 18216022
    [Abstract] [Full Text] [Related]

  • 38. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation.
    Chang TJ, Tseng HC, Liu MW, Chang YC, Hsieh ML, Chuang LM.
    Sci Rep; 2016 Mar 21; 6():23403. PubMed ID: 26997114
    [Abstract] [Full Text] [Related]

  • 39. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.
    Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S.
    J Hepatol; 2011 Jun 21; 54(6):1214-23. PubMed ID: 21145820
    [Abstract] [Full Text] [Related]

  • 40. Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival.
    Nakashima K, Shimoda M, Hamamoto S, Tatsumi F, Hirukawa H, Tawaramoto K, Kanda Y, Kaku K.
    Mol Cell Endocrinol; 2012 Feb 26; 349(2):281-8. PubMed ID: 22108438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.